For any media enquiries,

Please contact: info@stabilitech.com

PRESS RELEASE

iosBio takes next step in race for a vaccine, announces BioCell as manufacturer for OraPro-COVID-19

Burgess Hill, UK, 12 June 2020 STABILITECH BIOPHARMA LTD (“iosBio”), a UK biotechnology company developing next generation vaccines and biopharmaceuticals, has announced today a partnership with BioCell Corporation (New Zealand) to manufacture its oral coronavirus vaccine, OraPro-COVID-19. Read more

Downloadable media assets

Press release doc
https://iosbio.com/wp-content/uploads/2020/05/iosBio-Biopharma-earns-prestigious-position-on-WHO-list-of-vaccine-developers-2.docx iosBio Logo

PRESS RELEASE

iosBio Biopharma earns prestigious position on WHO list of vaccine developers

Burgess Hill, UK, 11 May 2020 STABILITECH BIOPHARMA LTD (“iosBio”), a UK biotechnology company developing next generation vaccines and biopharmaceuticals,  announces today that, they have been recognised on a global level by the World Health Organisation (WHO) as a vaccine developer. Read more

Downloadable media assets

Press release doc
https://iosbio.com/wp-content/uploads/2020/05/iosBio-Biopharma-earns-prestigious-position-on-WHO-list-of-vaccine-developers-2.docx iosBio Logo

PRESS RELEASE

iosBio Biopharma strengthens leadership team, as Jeffrey Almond joins the board in race to develop oral vaccine for COVID-19

Burgess Hill, UK, 07 May 2020 STABILITECH BIOPHARMA LTD (“iosBio”), a UK biotechnology company developing next generation vaccines and biopharmaceuticals, has today announced that Professor Jeffrey Almond will be joining the board as they step up their efforts in search of a vaccine for COVID-19. Read more

Downloadable media assets

Press release doc
https://iosbio.com/wp-content/uploads/2020/05/10821890-iosBio-strengthens-board-with-the-appointment-of-Jeffery-Almond.docx iosBio Logo

PRESS RELEASE

iosBio Biopharma joins race to develop COVID-19 vaccine delivering unique double immunity using self-administered capsules

Burgess Hill, UK, 30 April 2020 STABILITECH BIOPHARMA LTD (“iosBio”), a UK biotechnology company developing next generation vaccines and biopharmaceuticals, has announced today that, it is seeking an investment of £6m to fund clinical trials and manufacturing of an oral coronavirus vaccine, OraPro-COVID-19. Read more

Downloadable media assets

Press release doc Full Zip Download
iosBio-Biopharma-joins-race-to-develop-COVID-19-vaccine-delivering-unique-double-immunity-using-self-administered-capsule iosBio_press_release_media_download iosBio Logo

iosBio in the media

The Washington Post

France 24

Virus-stung UK banks on vaccine drive – 22/05/2020

Genetic Engineering & Biotechnology News

COVID-19 candidates: iosBio Biopharma – 19/05/2020

The Daily Telegraph

Britain in coronavirus lockdown, in pictures – 19/05/2020

Pharmaceutical-Technology.com

WHO recognises UK’s iosBio as a Covid-19 vaccine developer  – 12/05/2020

EPR – EUROPEAN PHARMACEUTICAL REVIEW

Novel thermally-stable COVID-19 vaccine capsule developed – 19/03/2020

Click through each Tab below to download resources.

iosBio media FAQs

iosBio media images

Clinical Trials: An Overview

OraPro-COVID-19 Mucosal & Systemic Immunity: An Overview

COVID-19

  • Millions of people infected.
  • Billions of people affected.
  • Trillions of dollars invested.

The world is fighting back.

iosBio is part of that fight – you can be too.

The OraPro-COVID-19. A coronavirus vaccine that delivers double immunity via a capsule that may be delivered by post that can be swallowed. No needles, no doctors or nurses, no queues for a vaccine, no risk of cross infection.

The Los Angeles Times’ Ralph Vartabedian says:

“The company has taken a harmless virus common in the human body and modified its genetic structure to include two genes that are responsible for the now famous spikes in the coronavirus. It is formulated into a pill that, when digested, would prompt the immune system to produce antibodies to attack the coronavirus spikes. The approach requires small amounts of the drug, meaning it would be easier to manufacture for universal consumption.”

Thermally stable, self-administered vaccines in capsule form are the future

 

We will soon be raising funds for clinical trials and the manufacture of the unique Ora-Pro-COVID-19 double immunity coronavirus vaccine in a capsule.